AdvisorShares Psychedelics ETF (PSIL)

M&A

Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray

Photo via Kris Tripplaar/Sipa USA/Newscom

The deal gives Eli Lilly access to a ⁠psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.

1 min read

Photo by Pretty Drugthings via Unsplash

ETF Upside

New Executive Orders Boost Weed and Psilocybin ETFs

Recent news of medical marijuana being reclassified and research into psychedelics being prioritized boosted some thematic funds, at least initially.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.